ES2525215T3 - Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado - Google Patents

Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado Download PDF

Info

Publication number
ES2525215T3
ES2525215T3 ES06746833.0T ES06746833T ES2525215T3 ES 2525215 T3 ES2525215 T3 ES 2525215T3 ES 06746833 T ES06746833 T ES 06746833T ES 2525215 T3 ES2525215 T3 ES 2525215T3
Authority
ES
Spain
Prior art keywords
chiral
optionally substituted
brs
nmr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06746833.0T
Other languages
English (en)
Spanish (es)
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2525215T3 publication Critical patent/ES2525215T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06746833.0T 2005-05-25 2006-05-25 Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado Active ES2525215T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005151864 2005-05-25
JP2006065762 2006-03-10
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
WOPCT/JP2006/310231 2006-05-23
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (1)

Publication Number Publication Date
ES2525215T3 true ES2525215T3 (es) 2014-12-19

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06746833.0T Active ES2525215T3 (es) 2005-05-25 2006-05-25 Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado

Country Status (20)

Country Link
US (4) US8084460B2 (https=)
EP (1) EP1889848B8 (https=)
JP (1) JP4323547B2 (https=)
KR (1) KR100912782B1 (https=)
CN (1) CN101228172B (https=)
AU (1) AU2006250390B2 (https=)
BE (1) BE2019C533I2 (https=)
BR (1) BRPI0610343B8 (https=)
CA (1) CA2609733C (https=)
DK (1) DK1889848T3 (https=)
ES (1) ES2525215T3 (https=)
FR (1) FR19C1042I2 (https=)
HU (1) HUS1900034I1 (https=)
MX (1) MX2007014588A (https=)
NL (1) NL300996I2 (https=)
PL (1) PL1889848T3 (https=)
PT (1) PT1889848E (https=)
RU (1) RU2403255C2 (https=)
TW (1) TWI311056B (https=)
WO (2) WO2006126529A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
JP5827123B2 (ja) * 2008-09-16 2015-12-02 ウェルズ ファーゴ バンク ナショナル アソシエイション 乱用の可能性が低いｐｅｇ化オピオイド
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
CN102906099A (zh) * 2010-05-13 2013-01-30 株式会社绿十字 作为神经保护剂的基于(+)-3-羟基吗啡喃的多环衍生物
KR101500915B1 (ko) * 2010-11-12 2015-03-10 시오노기세야쿠 가부시키가이샤 6,7-불포화-7-카르바모일 모르피난 유도체의 결정 및 그의 제조 방법
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
US11135217B2 (en) 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
BR9707136A (pt) 1996-01-10 1999-08-31 Smithkline Beecham Spa Derivados morfinóides condesados em heterociclo (ii)
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ES2278647T3 (es) * 1999-11-29 2007-08-16 Adolor Corporation Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides.
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
JP2004515455A (ja) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
EP1280529A2 (en) 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
PL368732A1 (en) * 2001-08-23 2005-04-04 Akzo Nobel N.V. C-14 oxidation of morphine derivatives
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
CN1288158C (zh) 2002-07-11 2006-12-06 东丽株式会社 用于预防恶心和呕吐的治疗剂或预防剂
US7164021B2 (en) * 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
CA2568249C (en) 2004-05-28 2014-12-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
KR101500915B1 (ko) 2010-11-12 2015-03-10 시오노기세야쿠 가부시키가이샤 6,7-불포화-7-카르바모일 모르피난 유도체의 결정 및 그의 제조 방법

Also Published As

Publication number Publication date
NL300996I2 (nl) 2019-07-30
PT1889848E (pt) 2014-12-09
EP1889848B1 (en) 2014-10-15
KR20080014791A (ko) 2008-02-14
EP1889848A4 (en) 2011-08-10
USRE46375E1 (en) 2017-04-25
BRPI0610343A2 (pt) 2010-06-15
US20090203723A1 (en) 2009-08-13
NL300996I1 (nl) 2019-07-03
AU2006250390A1 (en) 2006-11-30
FR19C1042I2 (fr) 2020-06-19
JP4323547B2 (ja) 2009-09-02
JPWO2006126637A1 (ja) 2008-12-25
US8084460B2 (en) 2011-12-27
USRE46365E1 (en) 2017-04-11
EP1889848A1 (en) 2008-02-20
US8536192B2 (en) 2013-09-17
CA2609733A1 (en) 2006-11-30
TWI311056B (en) 2009-06-21
AU2006250390B2 (en) 2010-07-08
WO2006126529A1 (ja) 2006-11-30
BRPI0610343B1 (pt) 2020-03-10
WO2006126637A1 (ja) 2006-11-30
TW200726470A (en) 2007-07-16
EP1889848B8 (en) 2014-12-17
HUS1900034I1 (hu) 2019-07-29
KR100912782B1 (ko) 2009-08-18
PL1889848T3 (pl) 2015-04-30
MX2007014588A (es) 2008-01-24
RU2403255C2 (ru) 2010-11-10
CA2609733C (en) 2011-07-19
US20120135978A1 (en) 2012-05-31
FR19C1042I1 (https=) 2019-08-09
BE2019C533I2 (https=) 2025-12-10
DK1889848T3 (en) 2014-12-01
CN101228172A (zh) 2008-07-23
CN101228172B (zh) 2013-04-03
BRPI0610343B8 (pt) 2021-05-25
RU2007148412A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
ES2525215T3 (es) Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado
EP3820574B1 (en) 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
EP3672949B9 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3885342B1 (en) Bicyclic inhibitors of pad4
EP2520567A2 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
US9630922B2 (en) 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
RU2475488C2 (ru) Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ
US8962642B2 (en) 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CN102955359A (zh) 盐、光致抗蚀剂组合物和用于制备光致抗蚀剂图案的方法
CN101420955B (zh) 可用作蛋白激酶抑制剂的二氢二氮杂*
US20250163049A1 (en) Fused bicyclic heterocyclyl compounds as usp1 inhibitors
US20180360803A1 (en) Pharmaceutical composition for treatment or prevention of nash
ES2561298T3 (es) Compuestos de aminometilquinolona
US20230416262A1 (en) Trpml modulators
US6103732A (en) Carboxylic acid derivatives, their production and use
TW202502345A (zh) Wrn抑制劑
US12177971B2 (en) Wiring board
JP4737495B2 (ja) エリスロマイシン誘導体
US6225478B1 (en) Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
ES2447891T3 (es) Procedimiento para la preparación de beta-cetonitrilos
US20040034076A1 (en) Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
RU2795850C2 (ru) Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
HK1129298B (en) Dihydrodiazepines useful as inhibitors of protein kinases